Tradestie Institutional Equity Comparison Engine

ATHA vs ABTS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ATHA Overall Edge

ATHA Captures Institutional Edge (2โ€“0 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Athira Pharma, Inc. Common Stock (ATHA) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, ATHA trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ABTS at N/M Forward P/E and -46.3% operating margin (-20.0% YoY). In options structure, ATHA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ABTS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ATHA N/M vs ABTS N/M Fwd P/E
Growth & Margin Winner ATHA
Op Margin 0.0% vs -46.3% ยท YoY +0.0% vs -20.0%
Momentum & Technical Winner ATHA
1Y +12.5% vs -95.1% ยท 52W Pos 80% vs 0%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
ATHA NASDAQ
Athira Pharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$6.75
-6.12% 1D
Market Cap $26.6M
1M Return +73.75%
1Y Return +12.5%
Forward P/E N/M
Unified AI Score
56.2 / 100 HOLD
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0
ABTS NASDAQ
Abits Group Inc Ordinary Shares
Finance Services
$0.31
-6.33% 1D
Market Cap $1.1M
1M Return -73.64%
1Y Return -95.1%
Forward P/E N/M
Unified AI Score
50.5 / 100 HOLD
Tech 50.0 Fund 55.0 Flow 50.0 Mom 59.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ATHA +12.5% ABTS -95.1% Spread: +52.44 pp (ATHA Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ATHA TTM Op. Margin: 0.0% ABTS TTM Op. Margin: -46.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ATHA vs ABTS. Trailing 12-month operating profitability (ATHA 0.0% vs ABTS -46.3%) and valuation multiples (ATHA N/M vs ABTS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ATHA (6) vs ABTS (2)
Institutional Metric ATHA ABTS Criterion Row Winner
Market Capitalization Scale $26.6M $1.1M Larger Scale ATHA
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -20.0% Higher Growth ATHA
Operating Margin (TTM) Profitability 0.0% -46.3% Higher Margin ATHA
Net Profit Margin Profitability 0.0% -60.8% Higher Margin ATHA
Return on Equity (ROE) Capital Efficiency -89.4% -60.0% Higher ROE ABTS
52-Week Range Position Momentum 80% ($0โ€“$8) 0% ($0โ€“$7) Stronger Trend ATHA
Beta / 30D Volatility Risk Regime 6.17ฮฒ ยท 241% Vol 1.70ฮฒ ยท 224% Vol Lower Realized Risk ABTS
Unified Institutional Score Composite Signal 56.2 / 100 (HOLD) 50.5 / 100 (HOLD) Higher Composite ATHA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ATHA vs ABTS Buy Guide
ATHA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ATHA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ABTS UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ABTS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ATHA nor ABTS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.